Pfizer, AstraZeneca, Cancer Research explore 'Matrix' of stratified meds
This article was originally published in Scrip
Executive Summary
Pfizer and AstraZeneca will be opening up libraries of their drugs to charity Cancer Research UK under a new partnership, which is aiming to create a "pioneering" clinical trial in advanced lung cancer. The"National Lung Matrix" trial is aimed at finding the right treatment from a selection of different drugs for each patient rather than studying the effects of any one specific medicine in a patient population.